Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMFS-202-302
- Development stage
- Unknown
- Lead developer
- Neurocentria
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MMFS-202-302 is an investigational small molecule drug developed for the treatment of schizophrenia and schizoaffective disorder, particularly in patients with stable levels of positive symptoms. It acts as a DKK1 inhibitor, representing a novel mechanism of action in this therapeutic area. The drug has been studied as an adjunctive oral therapy to atypical antipsychotic medications, with the primary goal of improving cognitive deficits—specifically working memory—in affected patients. Clinical trials have also evaluated its impact on other cognitive domains and both positive and negative symptoms of schizophrenia[1][2].
02
Targets
DKK1 (Dickkopf-related protein 1)
Beyond the preview
Go deeper on MMFS-202-302.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMFS-202-302.